Universität zu Köln

Piechotta, Vanessa, Mellinghoff, Sibylle C., Hirsch, Caroline ORCID: 0000-0002-2011-1010, Brinkmann, Alice, Iannizzi, Claire, Kreuzberger, Nina ORCID: 0000-0001-8922-0488, Adams, Anne ORCID: 0000-0003-3286-1131, Monsef, Ina, Stemler, Jannik, Cornely, Oliver A. ORCID: 0000-0001-9599-3137, Broeckelmann, Paul J. and Skoetz, Nicole (2022). Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J., 12 (5). LONDON: SPRINGERNATURE. ISSN 2044-5385

Full text not available from this repository.

Abstract

The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM) appears limited due to disease and treatment-associated immune impairment. We conducted a systematic review of prospective studies published from 10/12/2021 onwards in medical databases to assess clinical efficacy parameters, humoral and cellular immunogenicity and adverse events (AE) following two doses of COVID-19 approved vaccines. In 57 eligible studies reporting 7393 patients, clinical outcomes were rarely reported and rates of SARS-CoV-2 infection (range 0-11.9%), symptomatic disease (0-2.7%), hospital admission (0-2.8%), or death (0-0.5%) were low. Seroconversion rates ranged from 38.1-99.1% across studies with the highest response rate in myeloproliferative diseases and the lowest in patients with chronic lymphocytic leukemia. Patients with B-cell depleting treatment had lower seroconversion rates as compared to other targeted treatments or chemotherapy. The vaccine-induced T-cell response was rarely and heterogeneously reported (26.5-85.9%). Similarly, AEs were rarely reported (0-50.9% >= 1 AE, 0-7.5% >= 1 serious AE). In conclusion, HM patients present impaired humoral and cellular immune response to COVID-19 vaccination with disease and treatment specific response patterns. In light of the ongoing pandemic with the easing of mitigation strategies, new approaches to avert severe infection are urgently needed for this vulnerable patient population that responds poorly to current COVID-19 vaccine regimens.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Piechotta, Vanessa UNSPECIFIED UNSPECIFIED UNSPECIFIED Mellinghoff, Sibylle C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hirsch, Caroline UNSPECIFIED orcid.org/0000-0002-2011-1010 UNSPECIFIED Brinkmann, Alice UNSPECIFIED UNSPECIFIED UNSPECIFIED Iannizzi, Claire UNSPECIFIED UNSPECIFIED UNSPECIFIED Kreuzberger, Nina UNSPECIFIED orcid.org/0000-0001-8922-0488 UNSPECIFIED Adams, Anne UNSPECIFIED orcid.org/0000-0003-3286-1131 UNSPECIFIED Monsef, Ina UNSPECIFIED UNSPECIFIED UNSPECIFIED Stemler, Jannik UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED orcid.org/0000-0001-9599-3137 UNSPECIFIED Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Skoetz, Nicole UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-676262
DOI:	10.1038/s41408-022-00684-8
Journal or Publication Title:	Blood Cancer J.
Volume:	12
Number:	5
Date:	2022
Publisher:	SPRINGERNATURE
Place of Publication:	LONDON
ISSN:	2044-5385
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MESSENGER-RNA VACCINE; ANTIBODY-RESPONSE; IMMUNE-RESPONSES; T-CELL; SARS-COV-2; EFFICACY Multiple languages Oncology; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67626